CoreFirst Bank & Trust’s ARK Genomic Revolution ETF ARKG Stock Holding History

CoreFirst Bank & Trust’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,860	Closed	-$406K	–	392
2022 Q1	$406K	Buy	8,860 +3,420	+63%	+$163K	0.28%	86
2021 Q4	$333K	Buy	5,440 +350	+7%	+$24.2K	0.22%	100
2021 Q3	$380K	Buy	5,090 +1,435	+39%	+$120K	0.26%	90
2021 Q2	$339K	Buy	3,655 +200	+6%	+$17K	0.23%	100
2021 Q1	$306K	Buy	+3,455	New	+$343K	0.21%	105

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

CoreFirst Bank & Trust's ARKG Position: Q2 2022 in Review

CoreFirst Bank & Trust sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 8,860 shares — an estimated $406K sold.

CoreFirst Bank & Trust first reported a position in ARKG in Q1 2021 and held it in 5 quarters. The position peaked at $406K in Q1 2022. 334 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

CoreFirst Bank & Trust reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
CoreFirst Bank & Trust sold 8,860 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $406K.
CoreFirst Bank & Trust first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 5 quarters.
CoreFirst Bank & Trust's ARK Genomic Revolution ETF position peaked at $406K in Q1 2022.
334 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on CoreFirst Bank & Trust's 13F filing for Q2 2022, filed 16 Aug 2022.